SciELO - Scientific Electronic Library Online

vol.15 número2Seguimiento y adherencia al tratamiento antiosteoporótico desde enfermería en una fracture liaison service índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista de Osteoporosis y Metabolismo Mineral

versión On-line ISSN 2173-2345versión impresa ISSN 1889-836X


GONZALEZ-MACIAS, Jesús  y  OLMOS-MARTINEZ, José Manuel. Romosozumab: confusion regarding its indications. Rev Osteoporos Metab Miner [online]. 2023, vol.15, n.2, pp.81-87.  Epub 25-Sep-2023. ISSN 2173-2345.

Romosozumab is undoubtedly an excellent drug to treat osteoporosis. However, its high price—much higher than antiresorptive drugs—initially led to accepting that its indication should be limited to patients with particularly high risk of fracture. However, the implementation of this idea into the routine clinical practice has been challenging. Firstly, different terms (“very high risk”, “high risk”, “severe osteoporosis”) have been used to describe such indications, and the specific meaning of each term changes from one author to the next. On the other hand, without enough scientific basis, concepts have been introduced to expand the drug indications to the point of proposing its universal or near-universal use (“imminent risk”, initiation of anabolic treatment for osteoporosis universally or quasi-universally). All this has created confusion among prescribing physicians and led to overly restrictive regulations imposed by health authorities regarding its use. This manuscript delves into these and other ideas in detail.

Palabras clave : Romosozumab; Trials; Osteoporotic fracture.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )